Non-opioid advantage Position Recro Pharma’s non-addictive, non-opioid injectable meloxicam and Dex-IN as safer analgesic options with potentially fewer opioid-related side effects, aligning with hospitals and ambulatory care centers seeking to reduce opioid use in post-operative pain management.

Hospital focused Leverage the company’s specialization in hospital and ambulatory care settings, emphasizing streamlined manufacturing-capacity, validated pipeline candidates, and potential for integration into peri-procedural and post-operative pain protocols.

Manufacturing footprint Highlight the 97,000 square foot DEA-licensed facility with multiple commercial products and royalty streams as a scalable, reliable supply source for CDMO partnerships, contract manufacturing, and potential contract-for-sale opportunities.

Strategic partnerships Target opportunities with government and research organizations (NCATS/NIH) and biopharma partners demonstrated by past collaborations to expand development and manufacturing contracts, increasing revenue channels beyond core products.

Leadership and ESG Utilize recent executive hires in quality, supply chain, people, culture and ESG to strengthen compliance, operational excellence, and customer-facing trust, enabling differentiated service levels and favorable contracting terms.